OCGN Stock News and Price: Ocugen rips higher on WHO optimism
Premium|Take advantage of 60% OFF on your first month.
Grab this special offer, it's 7 months for FREE deal! And access ALL our articles and analysis.
You have reached your limit of 5 free articles for this month.
BLACK FRIDAY SALE! 60% OFF!
Grab this special offer, it's 7 months for FREE deal! And access ALL our articles and analysis.
CLAIM OFFER- Ocugen has the rights to distribute Bharat Biotech's COVID-19 vaccine in the US and Canada.
- The WHO is meeting on Wednesday to decide whether Covaxin can receive Emergency Use Listing.
- OCGN stock is up more than 600% this year.
Ocugen (OCGN) opened up 8.1% to $15.11 on Tuesday, the day after it surged by 18.1% to $13.98. The company is a little-known biopharma player that studies gene therapies to cure blindness, but that is not the reason OCGN stock is soaring.
OCGN News: Good news that might not help Ocugen either way
Instead, Ocugen owns the rights to sell Bharat Biotech’s COVID-19 vaccine in the US and Canada, and the World Health Organization (WHO) is meeting on Wednesday to determine whether to give the vaccine – Covaxin – an Emergency Use Listing (EUL) that would allow it to be purchased for use in more than 100 countries as part of the COVAX Facility.
If Covaxin is approved, it will greatly benefit Bharat, but will it help Ocugen’s bottom line? The US and Canada are donors rather than beneficiaries of the COVAX Facility, which is an initiative of the Vaccines Alliance.
The more important test for OCGN stock is whether Canada approves its application to distribute there. Likewise, Ocugen is hoping to get the US Food & Drug Administration to approve its phase-3 study for Covaxin.
i'm not saying $OCGN will be $MRNA or close to it. but i am saying i'm going to hold long, steady and strong i want to see the FULL POTENTIAL of where Ocugen will be. it's an investment. pic.twitter.com/tBB1kcU4pY
— Will Bh (@wilfriedboh) October 30, 2021
i'm not saying $OCGN will be $MRNA or close to it. but i am saying i'm going to hold long, steady and strong i want to see the FULL POTENTIAL of where Ocugen will be. it's an investment. pic.twitter.com/tBB1kcU4pY
— Will Bh (@wilfriedboh) October 30, 2021
OCGN key statistics
| Market Cap | $2.8 billion |
| Price/Earnings | N/A |
| Price/Sales | N/A |
| Price/Book | 20.2 |
| Enterprise Value | $2.2 billion |
| Gross Margin | N/A |
| Net Margin |
N/A |
| 52-week high | $18.77 |
| 52-week low | $0.27 |
| Short Interest | 28.7% |
| Average Wall Street Rating and Price Target | Hold $8.88 |
OCGN Stock Chart: Sell the news
Trading as high as $778.20 near its debut in December 2014, Ocugen is a stock that has trended down for years and lost as much as 99% of value in the seven years since. It was trading for mere pennies in 2020 but is up more than 600% this year.
Still, OCGN has a penchant for volatile spikes that make retail traders love it. Just as fast though, these spikes typically diminish within a day or two. At Monday’s closing price of $13.98, the clear target is $16.20. This was the swing high from May 3. That spike was much lower than the February 8 spike that went as high as $18.77. The closing prices on those days were quite close – $15.68 and $15.81. This area may also act as resistance as some traders decide to bail.
FXStreet View: Sell the news. No matter which way the decision goes at the WHO advisory meeting on Wednesday, OCGN stock is likely to sell off as it has in the past. If you are holding on Tuesday, now is the time to book profits.
OCGN daily chart
- Ocugen has the rights to distribute Bharat Biotech's COVID-19 vaccine in the US and Canada.
- The WHO is meeting on Wednesday to decide whether Covaxin can receive Emergency Use Listing.
- OCGN stock is up more than 600% this year.
Ocugen (OCGN) opened up 8.1% to $15.11 on Tuesday, the day after it surged by 18.1% to $13.98. The company is a little-known biopharma player that studies gene therapies to cure blindness, but that is not the reason OCGN stock is soaring.
OCGN News: Good news that might not help Ocugen either way
Instead, Ocugen owns the rights to sell Bharat Biotech’s COVID-19 vaccine in the US and Canada, and the World Health Organization (WHO) is meeting on Wednesday to determine whether to give the vaccine – Covaxin – an Emergency Use Listing (EUL) that would allow it to be purchased for use in more than 100 countries as part of the COVAX Facility.
If Covaxin is approved, it will greatly benefit Bharat, but will it help Ocugen’s bottom line? The US and Canada are donors rather than beneficiaries of the COVAX Facility, which is an initiative of the Vaccines Alliance.
The more important test for OCGN stock is whether Canada approves its application to distribute there. Likewise, Ocugen is hoping to get the US Food & Drug Administration to approve its phase-3 study for Covaxin.
i'm not saying $OCGN will be $MRNA or close to it. but i am saying i'm going to hold long, steady and strong i want to see the FULL POTENTIAL of where Ocugen will be. it's an investment. pic.twitter.com/tBB1kcU4pY
— Will Bh (@wilfriedboh) October 30, 2021
i'm not saying $OCGN will be $MRNA or close to it. but i am saying i'm going to hold long, steady and strong i want to see the FULL POTENTIAL of where Ocugen will be. it's an investment. pic.twitter.com/tBB1kcU4pY
— Will Bh (@wilfriedboh) October 30, 2021
OCGN key statistics
| Market Cap | $2.8 billion |
| Price/Earnings | N/A |
| Price/Sales | N/A |
| Price/Book | 20.2 |
| Enterprise Value | $2.2 billion |
| Gross Margin | N/A |
| Net Margin |
N/A |
| 52-week high | $18.77 |
| 52-week low | $0.27 |
| Short Interest | 28.7% |
| Average Wall Street Rating and Price Target | Hold $8.88 |
OCGN Stock Chart: Sell the news
Trading as high as $778.20 near its debut in December 2014, Ocugen is a stock that has trended down for years and lost as much as 99% of value in the seven years since. It was trading for mere pennies in 2020 but is up more than 600% this year.
Still, OCGN has a penchant for volatile spikes that make retail traders love it. Just as fast though, these spikes typically diminish within a day or two. At Monday’s closing price of $13.98, the clear target is $16.20. This was the swing high from May 3. That spike was much lower than the February 8 spike that went as high as $18.77. The closing prices on those days were quite close – $15.68 and $15.81. This area may also act as resistance as some traders decide to bail.
FXStreet View: Sell the news. No matter which way the decision goes at the WHO advisory meeting on Wednesday, OCGN stock is likely to sell off as it has in the past. If you are holding on Tuesday, now is the time to book profits.
OCGN daily chart
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.